Stock XVIVO XVIVO PERFUSION AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Xvivo Perfusion AB

Equities

XVIVO

SE0004840718

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:47 2024-05-03 EDT 		5-day change 1st Jan Change
378 SEK +2.02% Intraday chart for Xvivo Perfusion AB +1.34% +14.72%
04-24 Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest DJ
04-24 Transcript : Xvivo Perfusion AB, Q1 2024 Earnings Call, Apr 24, 2024

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company returns high margins, thereby supporting business profitability.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • With an expected P/E ratio at 160.93 and 74.6 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
XVIVO PERFUSION AB Stock Xvivo Perfusion AB
+14.72% 1.1B
B
ABBOTT LABORATORIES Stock Abbott Laboratories
-3.79% 184B
C+
MEDTRONIC PLC Stock Medtronic plc
-0.84% 108B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-3.75% 67.8B
A
DEXCOM, INC. Stock DexCom, Inc.
+3.45% 51.05B
B-
CENCORA, INC. Stock Cencora, Inc.
+9.04% 44.67B
B-
HOYA CORPORATION Stock Hoya Corporation
+3.40% 41.78B
B+
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+3.66% 26.59B
A-
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.21% 26.78B
B
TERUMO CORPORATION Stock Terumo Corporation
+15.23% 25.86B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. XVIVO Stock
  4. Ratings Xvivo Perfusion AB